| pubmed-article:17064986 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17064986 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17064986 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:17064986 | lifeskim:mentions | umls-concept:C0038250 | lld:lifeskim |
| pubmed-article:17064986 | lifeskim:mentions | umls-concept:C0079459 | lld:lifeskim |
| pubmed-article:17064986 | lifeskim:mentions | umls-concept:C0005767 | lld:lifeskim |
| pubmed-article:17064986 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:17064986 | lifeskim:mentions | umls-concept:C0300926 | lld:lifeskim |
| pubmed-article:17064986 | lifeskim:mentions | umls-concept:C0457343 | lld:lifeskim |
| pubmed-article:17064986 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:17064986 | pubmed:dateCreated | 2006-10-26 | lld:pubmed |
| pubmed-article:17064986 | pubmed:abstractText | The aim of the study was to investigate the feasibility of mobilizing Philadelphia chromosome negative (Ph-) blood stem cells (BSC) with intensive chemotherapy and lenograstim (G-CSF) in patients with CML in first chronic phase (CP1). During 1994-1999 12 centers included 37 patients <56 years. All patients received 6 months' IFN, stopping at median 36 (1-290) days prior to the mobilization chemotherapy. All received one cycle of daunorubicin 50 mg/m2 and 1 hour infusion on days 1-3, and cytarabine (ara-C) 200 mg/m2 24 hours' i.v. infusion on days 1-7 (DA) followed by G-CSF 526 microg s.c. once daily from day 8 after the start of chemotherapy. Leukaphereses were initiated when the number of CD 34+ cells was >5/microl blood. Patients mobilizing poorly could receive a 4-day cycle of chemotherapy with mitoxantrone 12 mg/m2/day and 1 hour i.v infusion, etoposide 100 mg/m2/day and 1 hour i.v. infusion and ara-C 1 g/m2/twice a day with 2 hours' i.v infusion (MEA) or a second DA, followed by G-CSF 526 microg s.c once daily from day 8 after the start of chemotherapy. Twenty-seven patients received one cycle of chemotherapy and G-CSF, whereas 10 were mobilized twice. Twenty-three patients (62%) were successfully (MNC >3.5 x 10(8)/kg, CFU-GM >1.0 x 10(4)/kg, CD34+ cells >2.0 x 10(6)/kg and no Ph+ cells in the apheresis product) [n = 16] or partially successfully (as defined above but 1-34% Ph+ cells in the apheresis product) [n = 7] mobilized. There was no mortality during the mobilization procedure. Twenty-one/23 patients subsequently underwent auto-SCT. The time with PMN <0.5 x 10(9)/l was 10 (range 7-49) and with platelets <20 x 10(9)/l was also 10 (2-173) days. There was no transplant related mortality. The estimated 5-year overall survival after auto-SCT was 68% (95% CI 47 - 90%), with a median follow-up time of 5.2 years.We conclude that in a significant proportion of patients with CML in CP 1, intensive chemotherapy combined with G-CSF mobilizes Ph- BSC sufficient for use in auto-SCT. | lld:pubmed |
| pubmed-article:17064986 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17064986 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17064986 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17064986 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17064986 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17064986 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17064986 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17064986 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17064986 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17064986 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17064986 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17064986 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:17064986 | pubmed:issn | 1042-8194 | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:LjungmanPerP | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:BjörkholmMagn... | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:WahlinAndersA | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:StenkeLeifL | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:LöfvenbergEva... | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:PaulChristerC | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:HöglundMartin... | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:HastRobertR | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:GrimforsGunna... | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:SimonssonBeng... | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:LinderOlleO | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:MalmClaesC | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:NilssonPer-Gu... | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:TuressonIngem... | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:VilenLarsL | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:RödjerStigS | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:GahrtonGöstaG | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:ObergGunnarG | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:CarlsonKarinK | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:Olsson-Strömb... | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:ZettervallOll... | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:BraideIngerI | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:LernerRickard... | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:TidefeldtUlfU | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:UdenAnn-Marie... | lld:pubmed |
| pubmed-article:17064986 | pubmed:author | pubmed-author:WinqvistIngem... | lld:pubmed |
| pubmed-article:17064986 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17064986 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:17064986 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17064986 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17064986 | pubmed:pagination | 1768-73 | lld:pubmed |
| pubmed-article:17064986 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:meshHeading | pubmed-meshheading:17064986... | lld:pubmed |
| pubmed-article:17064986 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:17064986 | pubmed:articleTitle | Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. | lld:pubmed |
| pubmed-article:17064986 | pubmed:affiliation | Department of Internal Medicine, University Hospital, SE-751 85 Uppsala, Sweden. ulla.olsson.stromberg@akademiska.se | lld:pubmed |
| pubmed-article:17064986 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17064986 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17064986 | lld:pubmed |
